China's vaccine production is accelerating across the board as the first domestically produced vaccine has been approved for conditional marketing.
On January 5, 21st Century Business Herald learned from the Ministry of Industry and Information Technology that currently, three companies, Sinopharm Sinopharm Beijing Company, Sinopharm Sinopharm Wuhan Company, and Beijing Sinovac Zhongwei Company, have completed their 2020 production capacity construction tasks and have all the necessary equipment for large-scale production.
According to the conditions, its vaccine production has started the "acceleration" mode, and the company's personnel are working at full capacity with high intensity, racing against time and organizing production day and night.
Among them, Sinopharm Beijing Company's production capacity of the new coronavirus inactivated vaccine in 2021 can reach more than 1 billion doses, and the construction of the second phase of the Sinovac Zhongwei production line will increase the annual production capacity to more than 600 million doses.
The production capacity of these two companies alone exceeds 1.6 billion doses.
At present, countries such as Malaysia, Turkey, the Philippines, and Mexico have ordered Chinese vaccines, and Indonesia, Pakistan, and Mexico have also signed vaccine production agreements with China.
In the early stages of launch, there may be a certain supply and demand gap for Chinese vaccines.
However, the Ministry of Industry and Information Technology stated that 18 domestic companies have successively started to build new coronavirus vaccine production capacity. With the further improvement of the production capacity of new coronavirus inactivated vaccines and the gradual completion of production capacity construction of other technical route companies, China's new coronavirus vaccine production capacity can
To meet domestic large-scale vaccination needs.
The Ministry of Industry and Information Technology stated that on December 30, 2020, the new coronavirus inactivated vaccine of Sinopharm Beijing Company was approved by the State Food and Drug Administration for conditional marketing.
Previously, the new coronavirus inactivated vaccines of Sinopharm Wuhan Company and Beijing Sinovac Zhongwei Company were approved for emergency use. The vaccines of the above three companies have begun to vaccinate key groups.
The Ministry of Industry and Information Technology stated that in order to meet the current demand for COVID-19 vaccination for key groups, three companies, Sinopharm Sinopharm Beijing Company, Sinopharm Sinopharm Wuhan Company, and Beijing Sinovac Zhongwei Company, have started the "accelerated" mode and will not stop work or production during the New Year's Day holiday.
, the company's personnel work with high intensity and at full capacity, racing against time and organizing production day and night.
Among them, Sinopharm Beijing Company's 2021 new coronavirus inactivated vaccine production capacity can reach more than 1 billion doses.
Sinopharm Sinopharm Wuhan Company and Beijing Sinovac Zhongwei Company are also making every effort to accelerate the expansion of production capacity to ensure the demand for new coronavirus vaccination.
Zhang Jin, head of the production of the new coronavirus inactivated vaccine project of Sinopharm Beijing Company, recently introduced that one of the company's packaging lines can package 200,000 doses per day. In order to promote more vaccines to be launched before the Spring Festival, its employees have given up their rest days.
, working 24 hours a day.
Liu Peicheng, spokesperson of Sinovac Biotechnology Co., Ltd., said in an interview with the 21st Century Business Herald on January 5 that the new coronavirus vaccine production line currently completed and put into use by Sinovac has an annual production capacity of over 300 million doses. The second batch of vaccines recently completed
After the first phase of the production line construction is put into use, the annual production capacity will be increased to more than 600 million doses. "Based on market demand and available funds, the company may further expand production capacity in the future to make greater contributions to the accessibility and affordability of the global COVID-19 vaccine."
. ” In addition, Beijing Sinovac Zhongwei recently received an investment of more than US$500 million from China Biopharmaceuticals for the further development, capacity expansion and production of the new coronavirus inactivated vaccine Clive.
The Ministry of Industry and Information Technology stated that it is fully preparing for the large-scale production of the new coronavirus vaccine.
On the one hand, a special class has been set up to ensure the production of new coronavirus vaccines to track and schedule the production capacity of key companies every week; on the other hand, companies on various technical routes are required to simultaneously promote production capacity construction; in addition, the Ministry of Industry and Information Technology also guides companies
Conduct research and analysis on the supply risks of production materials, promote key materials to accelerate production technology research, organize upstream and downstream enterprises to strengthen the connection between supply and demand, and ensure the stability of the new coronavirus vaccine production supply chain.
It is worth noting that on December 31, 2020, Wang Jiangping, Vice Minister of the Ministry of Industry and Information Technology, once again visited Sinopharm Beijing Company and Beijing Sinovac Zhongwei Company to investigate the construction of new coronavirus vaccine production capacity.
He emphasized that it is necessary to steadily accelerate the expansion of production capacity, scientifically arrange production plans on the premise of ensuring vaccine quality and safety, maximize production potential, and make every effort to ensure the production and supply of new coronavirus vaccines.
According to the Ministry of Industry and Information Technology, three companies, Sinopharm Sinopharm Beijing Company, Sinopharm Sinopharm Wuhan Company, and Beijing Sinovac Zhongwei Company, have completed their 2020 production capacity construction tasks and have all the conditions for large-scale production. The production capacity construction of other companies is also progressing as planned.
advance in sequence.
At present, 18 domestic companies have begun to build new coronavirus vaccine production capacity.
In the next step, the ministry will continue to strengthen production scheduling, promote enterprises to further expand production capacity through a series of methods such as the transformation of production workshops and the improvement of production technology, and comprehensively organize and guarantee the production of new coronavirus vaccines.
At the press conference of the Joint Prevention and Control Mechanism of the State Council on December 31, 2020, Zeng Yixin, deputy director of the National Health Commission and head of the vaccine research and development team of the Scientific Research Group of the Joint Prevention and Control Mechanism of the State Council, said that China plans to establish population-wide immunity through vaccination
Barrier, the basic attribute of the vaccine is that it is a public product, and the price may change depending on the scale of use.
But a big premise is that it must be provided free of charge to everyone.